Despite limited comparative data, guidelines suggest the same concomitant unfractionated heparin (UFH) dose for all fibrin-specific thrombolytic agents in acute myocardial infarction. Since a supratherapeutic activated partial thromboplastin time (aPTT) correlates with adverse outcomes, clarifying effects of various agents on aPTT are needed. The present in vitro study evaluated the influence of alteplase (rt-PA), reteplase (r-PA), and tenecteplase (TNK) on aPTT prolongation. Blood samples from healthy volunteers (n 12) were treated with equipotent concentrations of rt-PA, r-PA, and TNK, with and without UFH. Samples of each treatment group were incubated at 378C; aPTT and fibrinogen activity were measured after 4 h. Mean aPTT values for rt-PA alone and r-PA alone were prolonged versus those of TNK alone (P 0.001 for both). Combined with UFH, rt-PA and r-PA increased the aPTT versus UFH alone (P < 0.05 for both). Interestingly, TNK UFH reduced the aPTT versus UFH alone (P < 0.001). A negative correlation existed between fibrinogen activity and aPTT for all treatments, except TNK alone. The present investigation illustrates that an agent with maximal fibrin specificity (TNK) has minimal effect on the aPTT, while agents with less fibrin specificity are more likely to prolong the aPTT, with and without UFH present. Blood Coagul Fibrinolysis 13:725-731 # 2002 Lippincott Williams & Wilkins.
Introduction
Over one million people in the United States experience an acute myocardial infarction each year [1] . Thrombolytic therapy in combination with unfractionated heparin (UFH) and aspirin is a firstline therapeutic option for establishing and maintaining coronary artery patency, and decreases morbidity and mortality in patients experiencing an acute myocardial infarction [2] [3] [4] . However, lifethreatening bleeding episodes are a major limitation of this treatment strategy [2] [3] [4] .
A primary predictor for the risk of bleeding is prolongation of the primary monitoring parameter of UFH -the activated partial thromboplastin time (aPTT). The Global Use Strategies to Open Occluded Coronary Arteries (GUSTO) investigators found a supratherapeutic aPTT in the early and late hours after thrombolytic therapy for acute myocardial infarction to be associated with increased bleeding and mortality [5] . Thrombolytic agents can breakdown fibrinogen, thereby forming fibrinogen degradation products, which are anticoagulants and, along with hypofibrinogenemia, are known to prolong the aPTT [6] [7] [8] . The greater the fibrinogen breakdown, the greater the aPTT prolongation. Currently, there are three Food and Drug Administration approved fibrin specific thrombolytic agents, and the degree of fibrinogen breakdown is inversely related to their fibrin specificity. Alteplase (rt-PA) is slightly more fibrin specific than reteplase (r-PA), and tenecteplase (TNK) is exceedingly more fibrin specific than rt-PA and r-PA [7, [9] [10] [11] .
The American College of Cardiology/American Heart Association Guidelines for the Management of Acute Myocardial Infarction recommend the same intravenous UFH dosing and aPTT goals for patients receiving any of the fibrin-specific thrombolytic agents [12] . However, the recommendations for concomitant UFH therapy do not discuss r-PA or the newer TNK. The recommended dosing of UFH appears to be based on various studies of fibrinspecific thrombolytic agents; however, a concurrent evaluation of all three agents and their effects on the aPTT in combination with UFH does not exist [6, 12, 13] . Since excessive prolongation of the aPTT increases bleeding and mortality, and complicates therapeutic monitoring, clarifying the effects of various fibrin-specific thrombolytic agents on the aPTT is needed. We aimed to evaluate the influence of fibrin specificity on aPTT prolongation. In this in vitro pilot study, we evaluated the effects of three fibrin-specific thrombolytic agents.
Methods
Fibrinogen activity, a measure of functional fibrinogen levels and an indirect indicator of fibrinogen breakdown, was measured for correlation analysis with aPTT and to validate the fibrin specificity of the agents. The two most commonly used fibrinspecific thrombolytic agents (rt-PA and r-PA), and the new highly fibrin-specific thrombolytic agent TNK, were evaluated alone and in combination with UFH.
Gathering and treatment of blood samples
The Human Subjects Institutional Review Board of our institution approved this study, and volunteers gave written informed consent to donate blood. Volunteers with a past history of any medical condition or currently taking any pharmacologic agent were not allowed to donate blood for this study. Baseline aPTT and fibrinogen determinations for the patients were not available. Seven blood samples from each healthy volunteer were obtained in 3.2% sodium citrate collection tubes. The whole blood samples were treated with the different thrombolytic agents, with and without UFH. Each blood sample was treated within 2 min of being obtained in exact draw collection tubes, with addition of study agents by pre-calibrated micropipettes. The treated sample groups included rt-PA alone, r-PA alone, TNK alone, UFH alone, rt-PA + UFH, r-PA + UFH, and TNK + UFH. The blood samples were treated as stated in order to evaluate the influence of thrombolytic agents on aPTT prolongation with and without the presence of UFH.
For valid comparison of aPTT prolongation by each thrombolytic agent, all samples treated with UFH had the same final concentration of UFH (0.3 U/ml). Similarly, all samples treated with rt-PA, r-PA, and TNK had final concentrations of 4.0, 4.2, and 8.6 ìg/ml, respectively. The UFH concentration utilized corresponds to the average concentration that elicits a therapeutic prolongation of the aPTT in acute myocardial infarction patients (as recommended by the American College of Cardiology/ American Heart Association Guidelines for the Management of Acute Myocardial Infarction) [14] . Concentrations of the thrombolytic agents utilized correspond to the average peak concentrations observed in acute myocardial infarction patients receiving doses of the particular agent recommended for a 70 kg patient [9, 15, 16] . Because thrombolytic agents used in clinical practice are administered in very different manners (i.e. single bolus versus double bolus versus bolus-infusion), use of steady-state concentrations for this in vitro study was not valid. Average peak concentrations optimize proteolysis, thereby allowing a valid relative comparison of the different agents.
After treating the blood samples with the assigned pharmacologic agent(s), each one was incubated in a water-warming bath at 378C for 4 h. The 4 h incubation represents the recommended time period from administration of thrombolytic and UFH therapy to the initial determination of the aPTT in clinical practice [12] . After centrifugation, the resulting plasma samples were immediately frozen at À808C, with the aPTT and fibrinogen activity determined at a later date.
Determination of the aPTT and fibrinogen activity
The aPTT was measured by a conventional clottable assay with a photo-optical coagulometer (Organon Teknika Corp., Durham, North Carolina, USA). Fibrinogen activity (Stago STA Fibrinogen; Diagnostica Stago, Inc., Parsippany, New Jersey, USA) levels were determined by a modified Clauss method in which exogenous thrombin is added to plasma and the rate of clot formation is measured. All measurements of the aPTT and fibrinogen activity were performed by Esoterix Coagulation, Inc. (Aurora, Colorado, USA).
Methods of data analysis
All data were encoded in electronic format and analyzed using SPSS Release 10.0. Basic descriptive statistics were produced. Repeated-measures analysis of variance with post hoc pair-wise comparisons were used to compare aPTT prolongation and fibrinogen activity between the groups. To adjust for sphericity assumptions associated with the repeated-measures analysis of variance, the Huynh-Feldt correction was applied. Paired-sample t tests were used to compare the combined treatment groups with the reference group (UFH alone). Bonferroni adjustments were applied to control type I error inflation. Pearson's bivariate correlation coefficients were calculated to correlate aPTT prolongation and fibrinogen activity levels for each drug treatment group. For all analyses, the a priori level of significance was 0.05.
Results
All volunteers (n ¼ 12) donating blood had no significant past medical histories and none were taking any medication at the time of blood donation. The volunteer population consisted of six males and six females (mean age, 29 years). When comparing the three thrombolytic groups (rt-PA alone, r-PA alone, TNK alone) and their relative impact on the measured variables, the groups differed significantly with respect to aPTT (P , 0.001) and fibrinogen activity (P , 0.001). The results of the post hoc analyses are presented in Table 1 . With respect to aPTT prolongation, rt-PA, r-PA, and TNK all differed significantly (85 s versus 62 s versus 32 s, respectively). The aPTT values for the TNK-treated samples were within the normal range (24-36 s) for 11 of 12 patients, with the twelfth patient's aPTT being only 41 s.
A second test consisted of comparing the three thrombolytic agents plus UFH (rt-PA + UFH, r-PA + UFH, TNK + UFH) to determine their impact on the aPTT and fibrinogen activity. The three combination groups differed significantly with respect to aPTT (P , 0.001) and fibrinogen activity (P , 0.001). The post hoc pair-wise comparisons of the three thrombolytic groups plus UFH found both rt-PA + UFH (234 s) and r-PA + UFH (228 s) compared with TNK + UFH (137 s) to be significantly different with respect to aPTT prolongation and fibrinogen activity levels (P , 0.001 for both variables). Comparing rt-PA + UFH and r-PA + UFH resulted in a significant difference in fibrinogen activity levels (P , 0.001), but not aPTT prolongation. The mean aPTT and fibrinogen activity values for the combinations are presented in Table 2 .
The third test compared each of the three thrombolytic groups plus UFH (rt-PA + UFH, r-PA + UFH, TNK + UFH) with the reference group (UFH alone) to determine their relative impact on aPTT prolongation and fibrinogen activity. The statistical findings are summarized in Table 2 . Each of the three treatment groups varied significantly from the reference group with respect to aPTT prolongation and fibrinogen activity levels. Combined with UFH, both rt-PA and r-PA had significantly longer aPTT values compared with UFH alone (234 and 228 s versus 187 s, respectively; P , 0.02 for both). In contrast, UFH + TNK sam- Data presented as the mean AE standard deviation. rt-PA, alteplase; r-PA, reteplase; TNK, tenecteplase. Ã P ¼ 0.024 versus rt-PA + UFH, y P ¼ 0.045 versus r-PA + UFH, { P , 0.001 versus TNK + UFH, } P , 0.001 versus rt-PA + UFH and r-PA + UFH, } P ¼ 0.003 versus TNK + UFH. Table 3 . For all treatment groups except TNK alone, which minimally reduced fibrinogen activity, aPTT prolongation had a significant negative correlation with fibrinogen activity levels.
Discussion

Prolongation of the aPTT and relationship with fibrin specificity
The principle finding of this in vitro study is that the effects of thrombolytic agents on aPTT prolongation are influenced by fibrin specificity. First, both rt-PA and r-PA alone significantly prolonged the aPTT compared with TNK alone, with rt-PA prolonging the aPTT greater than r-PA. TNK, an exceedingly more fibrin-specific agent than rt-PA and r-PA, did not prolong the aPTT outside of normal laboratory limits (24-36 s) when analyzed alone. These findings appear to be a reflection of the degree of fibrinogen breakdown exhibited in this study, as measured by fibrinogen activity. As a particular thrombolytic agent decreased fibrinogen activity levels, the aPTT was proportionally prolonged, as established by the negative correlation between fibrinogen activity and aPTT prolongation when the thrombolytic agents were analyzed alone. The mean fibrinogen activity level with TNK was in the normal laboratory reference range (160-350 mg/ dl), which reflects its minimal breakdown of fibrinogen, and is in accordance with the previously observed maximal fibrin specificity of this agent [7, 9, 11] . The aPTT prolongation observed with rt-PA alone is similar to that found by Agnelli and colleagues in pulmonary embolism patients [17] . Data of aPTT prolongation with r-PA and TNK was previously obscure.
Because thrombolytic therapy with fibrin-specific agents should be accompanied by UFH, it was necessary to consider the combinations of these agents. Both rt-PA and r-PA in combination with UFH prolonged the aPTT to similar extents, and were significantly greater than TNK + UFH. When compared with the reference group of UFH alone, both rt-PA + UFH and r-PA + UFH significantly prolonged the aPTT. Again, analysis demonstrated that increasing fibrinogen breakdown was related to increasing aPTT prolongation. The excessive decreases in fibrinogen activity with rt-PA + UFH and r-PA + UFH probably contributed to a potentiation of the aPTT compared with UFH alone. Although the difference in fibrinogen activity reduction between rt-PA + UFH and r-PA + UFH was similar to the difference in fibrinogen activity when rt-PA and r-PA were analyzed alone, the aPTT prolongation was not different when the drugs were analyzed in combination with UFH, a contrast to these agents analyzed alone. This finding suggests a greater aPTT potentiation with r-PA compared with rt-PA, when combined with UFH. Overall, both rt-PA and r-PA significantly potentiate the aPTT in vitro. Interestingly, TNK + UFH actually produced an attenuation of the aPTT prolongation compared with UFH alone. The observed minimal effect of TNK on fibrinogen activity levels was expected to produce negligible potentiation of the aPTT. Therefore, the attenuation of the aPTT with the combination of TNK + UFH was not anticipated. Because this is the first investigation to uncover such a finding, it is difficult to speculate the cause. A previous chromatographic binding study has shown that r-PA and rt-PA interact with UFH in vitro; however, this has not been explored in blood nor clinically [18] . Because our data shows that TNK alone does not influence the aPTT, and that TNK + UFH attenuates this parameter, a potential drug interaction between this thrombolytic agent and UFH must be considered. However, the presence of a true interaction either in vitro or in vivo, must still be systematically explored. Nevertheless, the maximally fibrin-specific agent (i.e. TNK) did not potentiate the aPTT in the present study.
The findings of the present study are in agreement with that of the GUSTO investigators, who found large discrepancies in fibrin specificity to result in a greater prolongation of the aPTT with the less fibrin-specific agent streptokinase compared with rt-PA [5] . This in vitro study is not only the first to specifically investigate the influence of TNK on aPTT prolongation, but more importantly is the first to directly compare all three fibrin-specific thrombolytic agents, subsequently uncovering a relationship between fibrin specificity and aPTT prolongation among these agents in vitro.
Implications of the present analysis
Although UFH anticoagulation in combination with thrombolytic therapy has been used in routine clinical practice for years, there is a need for further investigation to both understand and optimize its effects. The GUSTO trial investigators found that high aPTT values in the early and late hours after initiating thrombolytic therapy increased severe non-cerebral bleeding, intracranial hemorrhage, reinfarction, and mortality rates [5] . Current guidelines recommend the same initial UFH dose (60 U/ kg bolus and 12 U/kg per h infusion) to be used concomitantly with rt-PA, r-PA, and TNK, to achieve the same goal aPTT, despite a lack of evidence regarding the relative effects of these agents on aPTT prolongation [12] .
Recently, the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) trial showed that major bleeding rates were significantly higher with rt-PA compared with the exceedingly more fibrin-specific agent TNK [3] . While the same UFH dosing was utilized for both agents, the influence of the different combinations on aPTT prolongation was not reported. Again, relative increases in fibrinogen breakdown often leads to additional prolongation of the aPTT and correlates with the incidence of major bleeding [19] , and may have been a contributing factor to the increased risk of bleeding observed with rt-PA in the ASSENT-2 trial [3] . While a decrease in fibrinogen is critical to bleeding risk, the influence of aPTT on bleeding risk can be independent from fibrinogen breakdown. The international stroke trial found that the degree of anticoagulation with UFH, in the absence of fibrinogendegrading agents, did correlate with increased bleeding risk [20] ; thus supporting the contention that varied effects of different thrombolytic agents on aPTT prolongation, not simply fibrinogen breakdown, may independently contribute to bleeding risk. Also, due to the greater aPTT prolongation with a non-fibrin-specific agent and the associated increased risk of bleeding, concomitant intravenous UFH is not routinely used in combination with streptokinase [2] . Our investigation observed a similar finding related to aPTT prolongation and differences in fibrin specificity, except the agents we evaluated are all considered fibrin specific. Because the same UFH dose is recommended for all fibrinspecific agents -should our findings hold true in the clinical setting -global use of the same UFH dose for rt-PA, r-PA, and TNK would not be warranted.
In fact, this may already be the case. The GUSTO-III trial found similar rates of major bleeding with rt-PA and r-PA (approximately 7%), probably reflecting the similarities in fibrin specificity between these agents [4] . In the ASSENT-2 trial, the UFH dose was lowered and the major bleeding rates for rt-PA and TNK subsequently decreased (5.94 and 4.66%, respectively), with TNK rates being significantly less [3] . The decrease in major bleeding rates with rt-PA from the GUSTO-III trial to the ASSENT-2 trial reinforces that the UFH dosing is a key factor in minimizing this adverse outcome [3, 4] . The exceedingly greater fibrin specificity of TNK versus rt-PA and r-PA, along with the decreased risk of major bleeding with TNK, implies that a lower dose of UFH may be required with rt-PA and r-PA to approach the minimized bleeding rates observed with TNK. The data from the current investigation is in accordance with this observation. Also, it must be noted that the lack of ideal UFH dosing not only increases the bleeding potential, but may also complicate aPTT monitoring, thereby increasing the associated costs and use of resources.
Limitations of the analysis
Aside from being an in vitro study, there are limitations to address. First, prior literature shows r-PA to be slightly less fibrin specific than rt-PA, suggesting that our results of greater aPTT prolongation with rt-PA alone versus r-PA alone are paradoxical. The treatment concentration of r-PA utilized in the present study probably explains this finding [16] . Quality pharmacokinetic data of r-PA is somewhat obscure, and does not correspond to the methods commonly reported in measuring rt-PA and TNK pharmacokinetics. Thus, the utilized treatment concentration of r-PA may not precisely reflect the true fibrin specificity of this agent in relation to rt-PA and TNK. However, the treatment concentrations of rt-PA and TNK were taken from comparable well-performed pharmacokinetic trials of similar methodology, thereby making comparisons based on varied fibrin specificity valid [7, 9, 15] . The excess aPTT prolongation in UFH-treated samples was probably due to the absence of UFH metabolizing endothelial tissue found in vivo and also the use of UFH concentrations based on whole blood content rather than plasma. Nonetheless, a valid relative comparison of aPTT prolongation with each thrombolytic agent combined with UFH was maintained. The absence of a fibrin thrombus was not required in the present study, since the primary goal was not to measure variables of thrombus dissolution, but to determine the relative effects of varying fibrin specificity on aPTT prolongation. Prolongation of the aPTT is primarily a systemic circulation phenomenon, occurring independent of the presence of thrombus. Had a thrombus been present, the results may have been even more in favor of increasing fibrin specificity, given that the increasing fibrinspecific agent would have been acting more at the site of action, leaving less drug available to break down fibrinogen in whole blood. Finally, while fibrinogen breakdown is probably a primary contributor, degradation of other coagulation factors may also influence aPTT prolongation, but such analysis is outside the scope of this pilot study.
Overall, because the analysis was performed in whole blood and no thrombus was present in any of the samples, and the same UFH concentration was used with all thrombolytics, this was a valid relative comparison of the influence of three fibrin-specific thrombolytic agents on aPTT prolongation.
Conclusion
This in vitro study was performed to contribute to the understanding of the appropriateness of a common UFH dosing recommendation for all available fibrin-specific thrombolytic agents used for acute myocardial infarction. This relative comparison shows that an agent with maximal fibrin specificity (TNK) has minimal effect on the aPTT, while agents with less fibrin specificity are more likely to prolong the aPTT with and without UFH. Also, TNK appears to attenuate the action of UFH in vitro. In light of these results, a re-evaluation of UFH dosing in combination with each fibrinspecific thrombolytic agent used for acute myocardial infarction may be warranted in the clinical setting.
